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Abstract 
 
Objective – Perivascular adipose tissue (PVAT) exerts an anticontractile effect in response 
to various vasoconstrictor agonists and this is lost in obesity. A recent study reported that 
bariatric surgery reverses the damaging effects of obesity on PVAT function. However, PVAT 
function has not been characterised following weight loss induced by caloric restriction, 
which is often the first line treatment for obesity.   
 
Approach and Results – Contractility studies were performed using wire myography on 
small mesenteric arteries with and without PVAT from control, diet-induced obese, calorie 
restricted and sustained weight loss rats. Changes in the PVAT environment were assessed 
using immunohistochemistry. PVAT from healthy animals elicited an anticontractile effect in 
response to norepinephrine. This was abolished in diet-induced obesity through a 
mechanism involving increased local TNFα and reduced nitric oxide bioavailability within 
PVAT. Sustained weight loss led to improvement in PVAT function associated with 
restoration of adipocyte size, reduced TNFα and increased nitric oxide synthase function. 
This was associated with reversal of obesity-induced hypertension and normalisation of 
plasma adipokine levels, including leptin and insulin. 
 
Conclusions – We have shown that diet-induced weight loss reverses obesity-induced 
PVAT damage through a mechanism involving reduced inflammation and increased nitric 
oxide synthase activity within PVAT. These data reveal inflammation and nitric oxide 
synthase, particularly eNOS, as potential targets for the treatment of PVAT dysfunction 
associated with obesity and the metabolic syndrome.   
 
 
 
 
Abbreviations:  
eNOS, endothelial nitric oxide synthase; HFD, high fat diet; KPSS, high potassium 
physiological salt solution; L-NMMA, NG-monomethyl-L-arginine; NO, nitric oxide; NOS, nitric 
oxide synthase; PSS, physiological salt solution; PVAT, perivascular adipose tissue; TNFα, 
tumour-necrosis factor-alpha; WL, weight loss; WM, weight maintenance.  
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Introduction 
 
Obesity is one of the major causes of illness and death in the world, and is a significant 
public health burden currently affecting an estimated half a billion adults and 40 million 
children globally1. It is associated with many co-morbidities and overwhelming evidence 
supports the importance of obesity in the pathogenesis and progression of cardiovascular 
disease2. The rapidly increasing gap between the availability of medical therapies and the 
steadily rising rates of obesity emphasise the need for investigation into novel therapies to 
prevent the devastating effects of being overweight.  
 
Healthy perivascular adipose tissue exerts an anticontractile effect on adjacent arteries3-5.  
that is lost in both rodent models6-9 and human obesity and the metabolic syndrome5, 10 
suggesting that changes in PVAT function and morphology may contribute to vascular 
dysfunction associated with increased body weight5 and diabetes11, 12.  
 
The most obvious treatment for obesity is weight loss, which can be achieved through 
lifestyle changes and surgical methods. Bariatric surgery is an established method of 
reducing obesity-associated morbidity and the cardiovascular benefits have been clearly 
demonstrated13 14. The mechanisms that underlie these improvements are unclear but are 
likely to be a consequence of improvements in inflammatory and adipokine profiles15-17. Our 
studies demonstrate that bariatric surgery can reverse obesity-induced PVAT damage six 
months after surgery through reduction of adipose inflammation and increasing local 
adiponectin and nitric oxide (NO) bioavailability10. This correlated with reduced blood 
pressure and improvements in lipid profiles and blood glucose levels suggesting that the 
restoration of PVAT function could contribute to the cardiovascular benefits of losing weight.  
 
Bariatric surgery is not suitable for all obese patients meaning that simple lifestyle measures 
such as caloric restriction and increased exercise should not be ignored and are often the 
first line in treatment for obesity18. Few studies have been specially designed to determine 
the effects of weight loss produced by dietary intervention in obesity, however, the majority of 
clinical trials and animal studies have reported a beneficial effect of diet-induced weight loss 
on blood pressure13, 19, 20 and adipokine balance20-22, along with improvements in the 
inflammatory profile9, 22.  
 
Investigation into the mechanisms involved in any improvement in PVAT function could lead 
to identification of much needed novel therapeutic targets for the treatment of obesity-related 
hypertension and cardiovascular disease. Therefore, the present study was designed to 
explore changes in the PVAT environment that occur in obesity and to investigate the effects 
of diet-induced weight loss on PVAT anticontractile function. The present study tested the 
hypothesis that diet-induced weight loss would lead to the restoration of PVAT function 
through changes in local inflammation and NO bioavailability. We report that diet-induced 
obesity perturbs PVAT function through a mechanism involving inflammation and nitric oxide 
synthase (NOS) and the PVAT damage can be reversed by sustained weight loss and 
associated reduction in adipose inflammation and increased NOS availability. 
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Materials and Methods 
Materials and methods are available in the online-only Data Supplement.  
 
 
Results 
 
Weight loss reversed cardiometabolic damage induced by high fat diet. 
There were no significant differences in body weight of the rats prior to starting their 
respective diets (P=0.39). After 16 weeks of of consuming the 45% fat diet (HFD), animals 
were significantly heavier than controls (P< 0.01, Figure 1). Two groups of obese animals 
(WL and WM) were then subjected to caloric restriction for four weeks in order to induce 
weight loss. Caloric restriction produced a gradual reduction in body weight with animals 
losing an average of 130g by week 20, at which time the average body weight was no longer 
different from control (P=0.57, Figure 1). Animals consuming the HFD continued to gain 
weight and were heavier than controls at week 20. To assess whether the vascular effects of 
weight loss were altered following maintenance of body weight, rats in one of the groups 
(WM) were provided with 70 kcal/day for an additional four weeks and were able to maintain 
their body weight in comparison with control (P=0.89, Figure 1). Animals fed the HFD 
consumed significantly more calories than rats provided with a control diet (Supplementary 
Figure I, P<0.001), indicating that the animals did not compensate for the increased caloric 
content of the high fat diet by eating less. 
 
The cardiometabolic profile of animals with dietary interventions is shown in Table 1. HFD 
produced insulin resistance without overt diabetes as shown by the increase in fasting 
plasma insulin levels (P<0.0001) without a change in blood glucose levels (P=0.83). 
Hyperinsulinemia was reversed following caloric restriction (P<0.0001) and this was 
sustained following the four-week weight maintenance period (P<0.01) with no effect on 
blood glucose levels (P=0.85). Body weight did not have an effect on plasma total 
adiponectin levels (P=0.13). Plasma leptin levels were significantly increased compared to 
those of controls after eight weeks of high fat feeding (P<0.01, data not shown) and were 
142% greater than control by week 20 (P<0.0001). Hyperleptinemia was reversed following 
caloric restriction (P<0.001) and this reduction was sustained following the four-week weight 
maintenance period (P<0.001).  
 
Systolic and diastolic blood pressure did not change over the 20-week period in animals fed 
control diet. High fat feeding induced significant increases in both systolic (P<0.0001) and 
diastolic (P<0.0001) blood pressure. Increases in systolic blood pressure were reversed 
following four-week weight loss (control vs. WL: P=0.06) and this was maintained during the 
weight maintenance period (control vs. WM: P=0.09). Diastolic blood pressure was reduced 
following weight loss; however, it remained significantly elevated compared with control 
(P<0.01). Maintenance of body weight led to complete reversal of the hypertensive 
phenotype as diastolic blood pressure decreased to control levels (control vs. WM: P=0.37). 
Significant tachycardia was observed in diet-induced obesity (control: 299±5.0 vs. obese: 
335±6.9bpm, P<0.0001). Caloric restriction induced transient bradycardia (WL: 
246±10.9bpm, P<0.0001), however heart rate returned to control levels in following weight 
maintenance (WM: 294±8.1bpm, P=0.56) suggesting that the reduced heart rate was a 
consequence of extreme weight loss. 
 
The anticontractile capacity of PVAT is restored following sustained weight loss 
The presence of PVAT did not alter the contractile response evoked by stimulation with 
KPSS in any of the animal models used (Supplementary Figure II). Moreover, responses to 
KPSS were not altered by body weight (P=0.45) allowing contractile responses to be 
expressed as percentage KPSS.  
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The presence of PVAT reduced the vasoconstrictor response to norepinephrine in lean 
controls (P<0.0001, Figure 2A). However, the presence of PVAT did not alter the contractile 
response in vessels isolated from animals provided HFD (P=0.21, Figure 2B) and the 
contractile response of vessels with PVAT to norepinephrine was increased compared to 
controls (P= 0.03, Supplementary Figure IIIA), indicating that diet-induced obesity diminished 
the anticontractile capacity of PVAT. Weight loss induced by 50% caloric restriction did not 
reverse obesity-induced loss of PVAT anticontractile effect as responses were unaltered by 
the presence of PVAT (P=0.14, Figure 2C) and the vasoconstrictor response to 
norepinephrine remained elevated compared to controls (P=0.01, Supplementary Figure 
IIIA). However, maintenance of body weight for four weeks following caloric restriction led to 
restoration of the PVAT anticontractile function as the presence of PVAT reduced the 
contractile response to norepinephrine (P<0.0001, Figure 2D) and the response of vessels 
with PVAT was no longer different to controls (P=0.35, Supplementary Figure IIIA). Changes 
in body weight had no effect on the vasoconstrictor response to norepinephrine in 
endothelium intact vessels lacking PVAT (P=0.14, Supplementary Figure IIIB).  
 
Adipocyte hypertrophy and PVAT inflammation are reduced by weight loss 
Obesity produced an increase in adipocyte cross-sectional area (P<0.0001), which was 
reduced but not completely reversed following caloric restriction (obese vs. WL: P<0.0001, 
control vs. WL: P<0.0001). However, complete restoration of adipocyte size was observed 
following a four-week weight maintenance period (control vs. WM: P=0.67, Figure 3A and B). 
The change in adipocyte area positively correlated with change in body weight (r=0.73, 
P<0.0001). 
 
Eosinophil number within PVAT was reduced in diet-induced obesity (P<0.0001). Eosinophil 
number increased following caloric restriction but levels were not significantly different to 
either control or obese (P>0.05). However, eosinophil levels within PVAT were restored by 
weight maintenance (P=0.67, Figure 3C). Moreover, the number of eosinophils within PVAT 
negatively correlated with body weight (r=-0.41, P=0.04) 
 
TNFα staining intensity was significantly increased in PVAT from obese animals compared to 
control (P<0.0001) and staining remained high following four-week caloric restriction (control 
vs WL: P=0.0019, obese vs WL: P=0.07). However, the increased TNFα immunostaining 
was reversed by sustained weight loss (control vs WM: P=0.11, obese vs WM: P<0.0001, 
Figure 4). 
 
Immunostaining for CD68+ cells was used to detect the total number of macrophages within 
PVAT (Figure 5). Macrophage infiltration occurred in diet-induced obesity (control vs obese: 
P<0.0001) and was decreased following caloric restriction (control vs WL: P>0.05, obese vs 
WL: P=0.02). However, macrophage number was further reduced to control levels following 
four-week weight maintenance (control vs WM: P=0.80, WL vs WM: P=0.0062).  
 
PVAT-derived NO contributes to restoration of PVAT anticontractility following 
maintenance of body weight 
Total eNOS expression within PVAT (Figure 6A and B) was reduced by diet-induced obesity 
(P=0.029) and remained reduced following four-week caloric restriction (P=0.04). Weight 
maintenance increased eNOS expression although levels were not significantly different to 
either control (P=0.94) or obese (P=0.34). 
 
Incubation of arteries with intact endothelium but lacking PVAT with the NOS inhibitor, L-
NMMA did not alter the vasoconstrictor response to norepinephrine (P=0.86, data not 
shown). However, the presence of L-NMMA increased the vasoconstrictor response to 
norepinephrine in PVAT intact vessels taken from control animals (P<0.0001, Figure 6C). 
Incubation of PVAT intact vessels with L-NMMA reduced the contractile response to 
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norepinephrine in obesity (P=0.0067, Figure 6D) but had no effect following weight loss 
induced by caloric restriction (P=0.06, Figure 6E). However, the effects of NOS inhibition 
were restored following weight maintenance as an increase in the contractile response was 
observed in vessels with PVAT in the presence of L-NMMA (P=0.0012, Figure 6F). 
Moreover, the presence of PVAT did not alter vasodilation in response to carbachol (P=0.81, 
Supplementary Figure IV).  
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Discussion 
 
The present study investigated the effects of obesity and diet-induced weight loss on the 
anticontractile properties of PVAT. The main findings were 1) diet-induced obesity perturbs 
PVAT function through a mechanism involving downregulation of NOS and increased 
inflammation; 2) the impaired anticontractile effect of PVAT associated with obesity can be 
ameliorated by sustained weight loss; and 3) sustained weight loss improves PVAT 
anticontractile function by reducing adipose inflammation and increasing NOS availability. 
These observations advance our understanding of how changes in the PVAT environment 
contribute to vascular dysfunction associated with obesity and how these may be reversed to 
restore normal PVAT function.    
 
Animals consuming the HFD rapidly gained weight becoming significantly heavier than those 
fed control diet indicative of the development of obesity. In agreement with human obesity23 
and rat models of diet-induced obesity21, 24, 25, high fat feeding was associated with 
hypertension and hyperleptinaemia. In contrast to the human phenotype, blood glucose 
levels were unaltered in obesity, however overt hyperglycaemia has rarely been reported in 
studies using Sprague Dawley rats26 and in agreement with our data, insulin resistance is 
common and its severity appears to be dependent on the fat content of the diet and duration 
of feeding27.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
The initial caloric restriction to 40 kcal/day was chosen to mimic human dieting28 and 
successfully produced a significant reduction in body weight over the four-week period, 
consistent with that observed in other rodent models21, 22, 29. Consistent with previous studies 
reporting the beneficial effects of weight loss on cardiovascular risk factors13, 21, 30, we also 
found circulating leptin and insulin levels were reduced to normal at the end of the four-week 
caloric restriction period. The increases in systolic blood pressure associated with obesity 
were reversed following caloric restriction, however diastolic blood pressure was only 
restored to control levels at the end of the four-week weight maintenance period suggesting 
that reversal of obesity-induced hypertension required sustained weight loss. The cause of 
the difference in the effect of caloric restriction on systolic versus diastolic blood pressure is 
unclear but may be a consequence of changes in peripheral resistance as this directly 
influences diastolic blood pressure. This is supported by the data presented in this study, as 
obesity-associated changes in the PVAT environment were still present following four-week 
caloric restriction, so increased diastolic blood pressure in weight loss animals might reflect 
the reduced PVAT anticontractile capacity. 
 
In line with studies of small arteries taken from obese patients5, 10 and rodent models of 
obesity 7-9, 31, we found that the anticontractile effect of PVAT was lost in the rat model of diet-
induced obesity. Obesity has been described as ‘the perfect storm’ as the storage of excess 
energy in adipocytes leads to hypertrophy and subsequent hypoxia, resulting in chronic 
inflammation and abnormalities in adipocyte function2. Adipocyte hypertrophy is one of the 
major hallmarks of obesity and similar to previous studies5, 9, 10 we found that the cross-
sectional area of adipocytes from mesenteric PVAT of obese animals was greatly increased. 
It has been shown that blood supply to adipocytes does not increase to compensate for 
enlarged adipocyte size32 and hypertrophied adipocytes are larger than the normal diffusion 
distance of oxygen within tissues33 suggesting that obese adipocytes exist in a state of 
hypoxia34. This results in the development of a chronic inflammatory state within the adipose 
tissue with increased production of pro-inflammatory cytokines, such as TNFα5, 10, 35, which 
was observed in PVAT from obese animals.  
 
Increased adipocyte size and subsequent inflammation within PVAT contribute to the 
obesity-induced loss of PVAT anticontractile effect. This is supported by previous work within 
our laboratory showing that experimental hypoxia, produced by gassing arteries with 95% 
nitrogen and 5% CO2 for 2.5 hours, significantly attenuated the anticontractile effect of PVAT 
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in both rat5, 36 and mouse37 mesenteric arteries through a mechanism that involved increased 
TNFα and IL-6. However, the damaging effects of obesity on PVAT function could not be 
reversed by incubation of arteries from obese patients with an anti-TNFα antibody5 
suggesting that chronic inflammation produces changes in adipocyte function and 
subsequent release of adipokines. 
 
The origins of pro-inflammatory cytokines within PVAT have not been explored, however 
previous studies have suggested increased levels of TNFα are a consequence of both 
increased adipokine secretion from the adipocytes and increased macrophage infiltration into 
the adipose tissue38, 39. Our data support a role for increased macrophage infiltration as the 
number of CD68+ cells within PVAT was increased in obesity. We accept that CD68+ may not 
be entirely macrophage specific as discussed previously by Kunisch et al.40 and it is feasible 
that increased adipose fibrosis may contribute to the changes observed41. However, studies 
using a mouse model of macrophage ablation showed a key role for macrophage activation 
in the loss of anticontractile effect when healthy PVAT is subjected to inflammatory insults36 
suggesting that the observed infiltration of pro-inflammatory macrophages contribute to the 
loss of PVAT anticontractile capacity in our animal model of diet-induced obesity. Moreover, 
a recent study reported increased macrophage infiltration in the aortic PVAT of obese mice 
when identified using either CD68 or F4/8042.  
 
Eosinophils play a role in sustaining anti-inflammatory M2 macrophages within the adipose 
tissue43 and recent studies within our laboratory have shown a loss of PVAT anticontractile 
effect in ΔdbGATA-F2 mice, which are deficient in eosinophils44. We show a reduction in the 
number of eosinophils within PVAT in diet-induced obesity and an inverse correlation with 
body weight, consistent with reports in perigonadal adipose tissue from obese mice43. This 
suggests that loss of eosinophils may contribute to the obesity-induced loss of PVAT 
anticontractile function, although the mechanism is currently unclear. 
 
Consistent with our data showing reduced eNOS levels in PVAT in obesity, several studies 
have reported decreased eNOS expression in white adipose tissue taken from animal 
models of obesity45, 46 suggesting that this may contribute to the observed reduction in NO 
activity.  Moreover, TNFα activity has been shown to induce eNOS downregulation in rodent 
white adipose tissue45 and contribute to endothelial dysfunction via downregulation of NOS in 
small mesenteric arteries47 suggesting that changes in eNOS activity could be the link 
between increased inflammation in PVAT and reduced function.  
 
Previous studies in human subcutaneous small arteries reported NOS inhibition had no effect 
on PVAT function in human obesity5, 10. We found that NOS inhibition produced a reduction in 
vascular contractility in obesity, suggesting that changes in NOS activity and subsequent 
reduced NO bioavailability contribute to the attenuation of PVAT function. The reasons for 
this are unclear, but increased levels of reactive oxygen species have been reported to lead 
to the uncoupling of eNOS resulting in the formation of perioxynitrite rather than NO31, 48. This 
is supported by previous data from our laboratory showing free radical scavengers can 
rescue PVAT anticontractile function in human obesity10 and the recent work of Xia et al. 
showing eNOS uncoupling within aortic PVAT from high fat fed mice42.  
 
A previous study reported that bariatric surgery could restore PVAT function by a reduction in 
adipose inflammation and increasing NO bioavailability10, therefore we investigated whether 
weight loss induced by dietary restriction could produce similar effects. In order to separate 
the effects of reduced energy intake and the physiological effects of weight loss, PVAT 
function was explored after a four-week caloric restriction period and following a weight 
maintenance period, in which animals were maintained on a healthy caloric intake for a 
further four-weeks leading to sustained weight loss. We found that the anticontractile effect of 
PVAT was restored following sustained weight loss and this was associated with reversal of 
hypertension and reduction in markers of the metabolic syndrome. However, the magnitude 
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of the PVAT effect was not as pronounced as that observed in control animals providing 
evidence for the existence of parallel signalling pathways and PVAT-derived relaxing factors 
mediating PVAT function.  
 
The improvement in PVAT function was associated with the restoration of adipocyte size to 
control levels, infiltration of eosinophils, decreased macrophage infiltration, reduction in 
PVAT TNFα and restoration of eNOS expression suggesting that reduced inflammation 
facilitates restoration of PVAT function. The effects of diet-induced weight loss on adipose 
inflammation have not been widely studied, however our findings are consistent with 
previous studies showing significant reductions in TNFα expression within mesenteric white 
adipose tissue following caloric restriction49. The increased eosinophil number within PVAT 
and their link to M2 macrophage stabilisation43; along with the reduced CD68+ cell staining 
indicate that reduction in macrophage infiltration may contribute to the restoration of PVAT 
function. Moreover, a recent study within our laboratory also supports the role of eosinophil 
infiltration in reversal of obesity-induced PVAT damage as reconstitution of eosinophils in 
ΔdbGATA-F2 mice restored the PVAT anticontractile capacity44.  
 
Along with the reduction in TNFα, we found that eNOS levels were restored following weight 
maintenance. This may be a consequence of the decreased macrophage numbers as this 
would reduce the high level of NO associated with uncoupling and also reduce TNFα 
production allowing restoration of normal eNOS expression.  Moreover, inhibition of NOS 
increased the contractile response to norepinephrine suggesting NOS function within PVAT 
was improved with a subsequent increase in NO bioavailability. This is supported by 
observations of increased plasma nitrite levels in obese patients following 12-week dietary 
intervention50. Moreover, enhanced NO bioavailability mediated increased endothelium-
dependent relaxation following 10% weight loss in obese patients51. Improvements in 
vascular responses to L-arginine were also reported following weight loss and correlated with 
decline in serum TNFα52 suggesting a role for reduced TNFα in the restoration of NO.  
 
We have shown that obesity is associated with a reversible reduction in NO bioavailability 
and restoration of adipose eNOS levels may also contribute to reversal of the metabolic 
syndrome. Overexpression of eNOS in mice was found to prevent high fat diet-induced 
weight gain and hyperinsulinaeima and attenuate diet-induced adipocyte hypertrophy 
through increased metabolic rate46. Moreover, eNOS has been suggested to be a key 
regulator of metabolic homeostasis following observations that deletion of the eNOS gene 
induced insulin resistance through its effects on vasodilation and insulin signalling within the 
skeletal muscle53, 54. This suggests that the observed improvement in insulin sensitivity may 
be a consequence of improved eNOS function and a defect in NO synthesis may represent a 
mechanism linking metabolic syndrome and cardiovascular disease. Taken together, these 
data reveal eNOS as a new target for the treatment of PVAT dysfunction associated with 
obesity and the metabolic syndrome.  
 
Four-week caloric restriction and its associated weight loss did not restore the anticontractile 
capacity of PVAT, even though systolic blood pressure returned to normal. Adipocyte 
hypertrophy and local inflammation were reduced within PVAT but not restored to control 
levels and NOS activity remained perturbed following weight loss. Moreover, diastolic blood 
pressure remained elevated suggesting that the damaging effects of obesity on PVAT 
function were not immediately reversed following return to control body weight and providing 
additional evidence for the role of PVAT in modulation of vascular tone.  
 
Bariatric surgery led to complete restoration of the PVAT anticontractile capacity within six 
months that was associated with reduced systolic blood pressure even though patients were 
still obese and had enlarged adipocytes within PVAT10. Similar to our results following 
sustained weight loss, where the anticontractile effect was restored, a reduction in TNFα 
staining associated with increased local NO bioavailability was reported within PVAT 
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following bariatric surgery suggesting that reductions in local inflammation are key to 
restoration of the PVAT anticontractile capacity.    
 
The results presented have shown that diet-induced obesity impairs PVAT anticontractile 
function through a mechanism involving increased TNFα and downregulation of NOS and 
that PVAT anticontractile function can be restored by sustained weight loss through reduction 
in local TNFα and increased NO availability. The findings support the targeting of 
inflammation and nitric oxide synthase for the treatment of PVAT dysfunction associated with 
obesity and the metabolic syndrome.  
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Highlights 
 The anticontractile effect of PVAT on adjacent arteries was abolished in diet-induced 
obesity.  
 Sustained diet-induced weight loss led to an improvement in PVAT function through 
reduced inflammation and restored NOS activity.  
 This study identifies inflammation and NOS as potential targets for the treatment of 
obesity-related hypertension.  
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Figure legends 
 
Figure 1. The effect of caloric intake on body weight. HFD increased body weight and 
this could be reversed by caloric restriction to 40 kcal/day (control vs obese: P < 0.0001, 
weight loss vs obese: P < 0.01). Data are expressed as mean ± S.E. **** indicates P < 
0.0001, two-way ANOVA with Bonferroni post hoc test, control: n = 12, obese: n = 14, weight 
loss: n = 12, weight maintain: n = 8. CR: caloric restriction; WM: weight maintenance period. 
 
Figure 2. Effect of diet-induced weight loss on PVAT anticontractile capacity. A, 
Healthy control animals: the presence of PVAT reduced the vasoconstrictor response to 
norepinephrine in vessels (P < 0.0001, n = 12). B, Diet-induced obesity: the presence of 
PVAT did not alter the contractile response  to norepinephrine (P = 0.21, n = 14). C, Diet-
induced weight loss: the anticontractile effect of PVAT was not restored (P = 0.14, n = 12) 
but D, Weight maintenance: PVAT anticontractile capacity was improved after an additional 
4-weeks (P < 0.0001, n = 8). Data are expressed mean ± S.E. * P < 0.05, ** P < 0.01, **** P 
< 0.0001, two-way ANOVA with Bonferroni post hoc test.  
 
Figure 3. Adipocyte hypertrophy is reversed by sustained weight loss. A, Mesenteric 
PVAT from control (i), obese (ii), weight loss (WL) (iii) and weight maintenance (WM) (iv) 
animals were stained with H&E to determine adipocyte area and number of eosinophils. 
Representative images were obtained at 40x magnification, scale bar represents 50 µm and 
arrows highlight eosinophils. B, Average adipocyte areas were increased in diet-induced 
obesity (control vs obese: P < 0.0001). Adipocyte hypertrophy was reduced following weight 
loss (obese vs weight loss: P < 0.0001) but not completely restored to control size (control vs 
weight loss: P < 0.001). The additional 4-week weight maintenance period reversed obesity-
induced adipocyte hypertrophy (control vs weight maintenance: P > 0.05). C, The number of 
eosinophils in mesenteric PVAT was reduced in diet-induced obesity (control vs obese: P < 
0.0001), this was increased following weight loss and eosinophil number was not significantly 
different to either control or obese. The additional 4-week weight maintenance period 
restored eosinophil number to control levels (controls vs weight maintain: P = 0.67). Data are 
expressed as mean ± S.E. * P < 0.05, *** P <0.001, **** P < 0.0001, one-way ANOVA with 
Tukey post hoc test. Control: n = 5, obese: n = 6, weight loss (WL): n = 5, weight maintain 
(WM): n = 9 animals. 100 consecutive adipocytes were analysed from 1 slide per animal.  
 
Figure 4. Inflammation within PVAT is reversed by sustained weight loss. A, 
Immunostaining for TNFα in mesenteric PVAT from control (i), obese (ii), weight loss (iii) and 
weight maintenance (iv) animals. Representative image of a negative control where samples 
were incubated with mouse IgG is shown (v).  Representative images were obtained at 40x 
magnification and scale bar represents 50 µm. B, Adipocytes were positive for TNFα to a 
higher extent in obese samples than control (P < 0.0001) and staining remained high 
following weight loss (control vs weight loss: P = 0.0019, obese vs weight loss: P = 0.07). 
Increased TNFα was reversed following the four-week weight maintenance period (control vs 
weight maintain: P = 0.11, obese vs weight maintain: P < 0.0001). Percentage staining 
intensity is expressed as mean ± S.E. * P < 0.05, ** P < 0.01, **** P < 0.0001, one-way 
ANOVA with Tukey post hoc test. Control: n = 5, obese: n = 6, weight loss (WL): n = 5, 
weight maintain (WM): n = 9 animals. 5 fields of view per slide and 1 slide per animal.  
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Figure 5. Macrophage infiltration is reversed by diet-induced weight loss. A, 
Immunostaining for CD68+ cells in mesenteric PVAT from control (i), obese (ii), weight loss 
(iii) and weight maintenance (iv) animals. Representative image of a negative control where 
samples were incubated with mouse IgG is shown (v). Representative images were obtained 
at 40x magnification, scale bars represent 75 µm and arrows highlight CD68+ cells. B, The 
number of CD68+ cells within PVAT was increased in diet-induced obesity (control vs obese: 
P < 0.0001).  This was reduced following caloric restriction (obese vs weight loss: P = 0.02) 
although further reductions were observed at the end of the 4-week weight maintenance 
period (weight loss vs weight maintain: P = 0.0062, control vs weight maintain: P = 0.80). 
Data are expressed mean ± S.E. * P < 0.05, ** P < 0.01, **** P < 0.0001, one-way ANOVA 
with Tukey post hoc test. Control: n = 5, obese: n = 6, weight loss (WL): n = 5, weight 
maintain (WM): n = 9 animals. 5 fields of view per slide and 1 slide per animal.  
 
Figure 6. Adipocyte-derived nitric oxide plays a key role in the restoration of the PVAT 
anticontractile capacity. A, Expression of total eNOS within PVAT was reduced by diet-
induced obesity (P = 0.03, n = 4) and remained reduced following 4-week caloric restriction 
(P = 0.04, n = 4). Sustained weight loss increased eNOS expression although levels were 
not significantly different to either control (P = 0.94, n = 4) or obese (P = 0.34, n = 4). Vessels 
with endothelium were incubated with 100 µM L-NMMA, a NOS inhibitor, for 30 minutes. B, 
Healthy control animals: Incubation of vessels with L-NMMA potentiated the vasoconstrictor 
response in the presence of PVAT (P < 0.0001, n = 12) C, Diet-induced obesity: L-NMMA 
reduced the contractile response to norepinephrine in vessels with PVAT (P = 0.0067, n = 
14). D, Diet-induced weight loss: NOS inhibition had no effect on the contractile response (P 
= 0.06, n = 8). E, Weight maintenance:  NOS inhibition increased the contractile response to 
norepinephrine (P = 0.0012, n = 7). Data are expressed mean ± S.E. * P < 0.05, ** P < 0.01, 
two-way ANOVA with Bonferroni post hoc test.  
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Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Control Obese Weight loss Weight 
maintain 
Systolic BP (mmHg) 119.9 ± 1.2† 142.4 ± 2.1* 124.1 ± 2.03† 116.0 ± 1.9†§ 
Diastolic BP (mmHg) 82.6 ± 1.2† 99.04 ± 1.6* 91.03 ± 1.7*† 84.40 ± 1.6†§ 
Blood glucose (mmol/L) 6.65 ± 0.27
 
 6.91 ± 0.26  6.66 ± 0.23 6.86 ± 0.24 
Insulin (ng/ml) 1.31 ± 0.18† 2.80 ± 0.35* 1.03 ± 0.19† 1.17 ± 0.08† 
Leptin (ng/ml) 3.46 ± 0.53† 8.40 ± 0.91* 4.17 ± 0.59† 2.62 ± 0.33† 
Adiponectin (µg/ml) 3.84 ± 0.27 4.24 ± 0.22 3.43 ± 0.38 4.58 ± 0.55 
Table 1. Diet-induced changes in cardiometabolic parameters can be reversed by 
caloric restriction.   
  Values are expressed as mean ± SE. *P<0.05 versus control; †P<0.05 versus obese, 
§P<0.05 versus weight loss one-way ANOVA with Tukey post hoc test, n = 8 – 12.  
Supplementary Figure I. Caloric intake. Food
intake was measured daily, animals on the HFD
consumed significantly more calories than those
on the control diet (P < 0.001). Data are
expressed as mean ± S.E, control: n = 6, obese:
n = 5, weight loss: n = 6.
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Supplementary Figure II. The presence of PVAT
had no effect on the contractile response to
KPSS in health or disease (P = 0.4511). Data are
expressed mean ± S.E.M * P < 0.05, one-way
ANOVA with Tukey post hoc test, control: n = 12,
obese: n = 14, weight loss (WL): n = 12, weight
maintain (WM): n = 8.
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Supplementary Figure III. Diet does not alter vasoconstriction in the absence of PVAT.
A, The contractile response of vessels with PVAT taken from obese animals was increased
compared to controls (P = 0.0332). The vasoconstrictor response remained elevated
compared to controls in vessels taken from weight loss animals (P = 0.0148). However,
weight maintenance led to improvement in the PVAT anticontractile capacity as the
response was no longer different to controls (P = 0.35). B, Body weight had no effect on
contractile response to norepinephrine in endothelium intact vessels lacking PVAT (P =
0.1353). Data are expressed as mean ± S.E. * P < 0.05, two-way ANOVA with Bonferroni
post hoc test. control: n = 12, obese: n = 14 , weight loss: n = 12 , weight maintain: n = 8.
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Supplementary Figure IV. PVAT has no
effect on endothelium-dependent dilation.
The presence of PVAT did not alter the dilation
response to carbachol in vessels taken from
control rats following constriction with 10 µmol/L
norepinephrine (P = 0.8057, n = 12). Data are
expressed as mean ± S.E.M. * P < 0.05, two-
way ANOVA with Bonferroni post hoc test.
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